奥比努图库单抗
滤泡性淋巴瘤
医学
美罗华
肿瘤科
化疗
淋巴瘤
危险系数
不利影响
内科学
CD20
外科
置信区间
作者
Robert Marcus,Andrew Davies,Kiyoshi Ando,Wolfram Klapper,Stephen Opat,Carolyn Owen,Elizabeth H. Phillips,Randeep Sangha,Rudolf Schlag,John F. Seymour,William Townsend,Marek Trněný,Michael Wenger,Günter Fingerle‐Rowson,Kaspar Rufibach,Tom Moore,Michael Herold,Wolfgang Hiddemann
标识
DOI：10.1056/nejmoa1614598
摘要
Rituximab-based immunochemotherapy has improved outcomes in patients with follicular lymphoma. Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody. We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI
SYLH
cdercder
昏睡的蟠桃
平常的毛豆
iNk
科研助手6
科研小民工
余味
落后导师
back you up
小海
kento
nozero
Auston_zhong
斯寜
HEIKU
tuanheqi
pluto
非而者厚
爱静静
皖公网安备34019202002308
